Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Sponsor
Universitair Ziekenhuis Brussel
Study ID
NCT00722969
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Patients with advanced or metastatic (stage IIIB-IV) non small cell lung cancer who have not received prior chemotherapy will be treated with erlotinib 150 mg once a day and sorafenib 400 mg twice a day. The objectives of the study are to assess the efficacy and safety of this combination treatment. Additional exploratory study objectives are correlation of biomarkers and imaging modalities potentially predictive for response and (progression free) survival.

Key Dates

First listed
Jul 28, 2008
Start date
Nov 30, 2007
Status verified
Mar 2009
Primary completion
Nov 30, 2008
Completion
Apr 30, 2009

Study Design

Enrollment
48 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: A

Primary Outcome Measure

Rate of non-progression at 6 weeks [ Time Frame: 6 weeks ]

Related Studies